J&J buys into Achillion's hep C pipeline for up to $1.1B
May 19, 2015 | By Damian Garde
Johnson & Johnson ($JNJ), fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' ($ACHN) pipeline of antiviral treatments.
Under the deal, J&J is making a $225 million investment in its partner and promising up to $905 million in milestone payments in order to get its hands on a group of in-development hep C treatments. The plan is to develop Achillion's drugs in combination with one another and, ideally, come up with a regimen thatcan cure the infection in as few as four weeks. Leading the pipeline is ACH-3102, Achillion's Phase II NS5A inhibitor, followed by the complementary ACH-3422 and sovaprevir.
Do the DD folks.
Goldman Sachs analysts said in a report on Tuesday that the new study shows efficacy across age groups gives HZ/su a meaningful edge over Zostavax, and GSK's product had the potential to achieve peak sales of around 1 billiopounds ($1.5 billion) a year.
Bloomberg Report- (CYBR ) Massive Growth Ahead
4/21/15( CYBR )
The ongoing series of well-publicized cyber attacks on large companies is causing businesses to become more concerned about protecting themselves from this threat. CyberArk ( CYBR ) software aims toverify that system users have access permission and is the only security software that can also take defensive steps against intruders. The advanced IT security company has "massive," growth potential.